Tag Archives: Evofem Biosciences

H.C. Wainwright Thinks Evofem Biosciences’ Stock is Going to Recover

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Evofem Biosciences (EVFM – Research Report) today and set a price target of $4.00. The company’s shares closed last Friday at $0.87, close to its 52-week low of $0.75. According

A Director at Evofem Biosciences (NASDAQ: EVFM) is Buying Shares

Yesterday, a Director at Evofem Biosciences (EVFM – Research Report), Kim Kamdar, bought shares of EVFM for $14.7K. This recent transaction increases Kim Kamdar’s holding in the company by 116.63% to a total of $27.4K. In addition to Kim Kamdar,

Analysts Offer Insights on Healthcare Companies: Evofem Biosciences (NASDAQ: EVFM) and Argenx Se (NASDAQ: ARGX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Evofem Biosciences (EVFM – Research Report) and Argenx Se (ARGX – Research Report) with bullish sentiments. Evofem Biosciences (EVFM) RBC Capital analyst

Evofem Biosciences (EVFM) Receives a Rating Update from a Top Analyst

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Evofem Biosciences (EVFM – Research Report) today and set a price target of $11.00. The company’s shares closed last Tuesday at $5.79. According to TipRanks.com, Selvaraju is a top 100

Evofem Biosciences (EVFM) Received its Third Buy in a Row

After H.C. Wainwright and RBC Capital gave Evofem Biosciences (NASDAQ: EVFM) a Buy rating last month, the company received another Buy, this time from Oppenheimer. Analyst Leland Gershell assigned a Buy rating to Evofem Biosciences yesterday and set a price

Evofem Biosciences (EVFM) Receives a Buy from Oppenheimer

Oppenheimer analyst Leland Gershell maintained a Buy rating on Evofem Biosciences (EVFM – Research Report) today and set a price target of $23.00. The company’s shares closed last Wednesday at $5.24. According to TipRanks.com, Gershell is a 5-star analyst with